Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

PWP vs CHYM: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PWP Captures Overall Composite Edge (47.4 HOLD vs 33.1 SELL), While CHYM Leads 4–2 on Growth & Valuation Pillars

PWP Overall Winner 6-Pillar Tally: PWP 2 – 4 CHYM Matrix Metrics: PWP 5 – 5 CHYM

As of Nov 16, 2026, Perella Weinberg Partners (PWP) captures the overall head-to-head institutional edge over Chime Financial, Inc. (CHYM) on higher Unified Composite conviction (47.4/100 HOLD vs. 33.1/100 SELL) after splitting the core matrix 5–5 (led by Growth & Scale, Profitability & Quality), while CHYM wins 4–2 across the 6-pillar growth and valuation breakdown. PWP trades at $12.89 (8.8x Forward P/E, 8.6% operating margin) versus CHYM at $34.25 (30.9x Forward P/E, 19.3% operating margin).

  • Growth vs. Quality Trade-Off: PWP earns the overall head-to-head edge with a stronger Unified Composite Score (47.4/100 HOLD vs. CHYM 33.1/100 SELL) and 1.50β · 55% Vol risk profile, whereas CHYM leads top-line expansion (+32.1% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: PWP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 40.4); meanwhile CHYM trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 73.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PWP vs CHYM
PWP NASDAQ Head-to-Head Winner
Perella Weinberg Partners Class A Common Stock
Finance Services
$12.89
-2.75% 1D
Market Cap $1.4B
TTM Revenue $776M
Forward P/E 8.8x
Beta / 30D Vol 1.50β · 55% Vol
Unified Composite Score
47.4 / 100 HOLD
Tech 25.0 Fund 40.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -8.6%), weak momentum, RSI 40
RSI-14: 40.4 · SMA20: $13.47 · SMA50: $14.15
CHYM NASDAQ
Chime Financial, Inc. Class A Common Stock
Finance Services
$34.25
+2.09% 1D
Market Cap $12.7B
TTM Revenue $14.3B
Forward P/E 30.9x
Beta / 30D Vol 1.44β · 37% Vol
Unified Composite Score
33.1 / 100 SELL
Tech 15.0 Fund 33.0 Flow 57.0 Mom 30.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 74
RSI-14: 73.7 · SMA20: $30.53 · SMA50: $29.95

6-Pillar Scorecard Institutional Category Breakdown (PWP 2 – 4 CHYM)

Columns: Metric · PWP · CHYM
1. Valuation Multiples CHYM
Forward P/E 8.8x 30.9x
Trailing P/E 34.5x 29.0x
PEG Ratio N/M N/M
EV / Revenue 1.8x 0.7x
2. Growth & Scale PWP
Revenue Growth (YoY) +52.7% +32.1%
Earnings Growth (YoY) +153.4% -33.8%
TTM Revenue (USD) $776M $14.3B
Market Cap $1.4B $12.7B
3. Profitability & Quality PWP
Gross Margin 97.1% 89.4%
Operating Margin 8.6% 19.3%
Net Profit Margin 4.3% 3.0%
Return on Equity (ROE) 15.2% 5.4%
4. Balance Sheet & Cash Flow CHYM
Cash Generation (TTM) N/A $2.27B
Cash Flow Margin N/A 15.8%
Net Cash / Leverage $0.81 Book/Sh · 15.2% ROE $2.77B Net Cash
Dividend Yield 2.02% None (0.00%)
5. Options & Positioning CHYM
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 66.2% (<1st %ile) 50.0% (15th %ile)
Put/Call OI Skew N/A 0.22x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat CHYM
OpEx & R&D Intensity N/A 70.1% of Rev ($10.1B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Capital Markets Operator Software - Application Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PWP (5) vs CHYM (5)
Institutional Metric PWP CHYM Criterion Row Edge
Market Capitalization
Scale
$1.4B $12.7B Larger Scale CHYM
Trailing P/E Ratio
Valuation
34.5x 29.0x Lower Multiple CHYM
Forward P/E Ratio
Valuation
8.8x 30.9x Lower Multiple PWP
Revenue Growth (YoY)
Growth
+52.7% +32.1% Higher Growth PWP
Operating Margin (TTM)
Profitability
8.6% 19.3% Higher Margin CHYM
Net Profit Margin
Profitability
4.3% 3.0% Higher Margin PWP
Return on Equity (ROE)
Capital Efficiency
15.2% 5.4% Higher ROE PWP
52-Week Range Position
Momentum
6% ($12–$26) 93% ($16–$36) Stronger Trend CHYM
Beta / 30D Volatility
Risk Regime
1.50β · 55% Vol 1.44β · 37% Vol Lower Realized Risk CHYM
Unified Institutional Score
Composite Signal
47.4 / 100 (HOLD) 33.1 / 100 (SELL) Higher Composite PWP
Trailing 12M Revenue (USD)
Operating Scale
$776M $14.3B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
97.1% 89.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.8x EV/Rev N/M PEG · 0.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($0.81 Book/Sh · 15.2% ROE) $2.27B ($2.77B Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CHYM +18.19 pp
PWP: -2.75% · CHYM: +15.44%
3M Horizon CHYM +27.58 pp
PWP: -20.25% · CHYM: +7.33%
6M Horizon CHYM +123.4 pp
PWP: -28.24% · CHYM: +95.16%
1Y Horizon CHYM +109.52 pp
PWP: -31.04% · CHYM: +78.48%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PWP vs CHYM. Trailing 12-month operating profitability (PWP 8.6% vs CHYM 19.3%) and valuation multiples (PWP 8.8x vs CHYM 30.9x Forward P/E) are benchmarked directly in Pillar 4 below.

PWP ADR TTM Benchmark FX-Normalized USD
TTM Revenue$776M
Gross Margin97.1%
Op. Margin8.6%
ROE / Fwd P/E15.2% · 8.8x
CHYM ADR TTM Benchmark FX-Normalized USD
TTM Revenue$14.3B
Gross Margin89.4%
Op. Margin19.3%
ROE / Fwd P/E5.4% · 30.9x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PWP UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 66.2%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PWP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CHYM CONSOLIDATION
48d in phase · OBV ACCUMULATION
Current IV 50.0%
IV Percentile 15th %ile
Put/Call OI Skew 0.22x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact CHYM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PWP Moat Profile Cyclical / Execution-Driven Positioning
Capital Markets Operator
Competes within the Capital Markets value chain with $1.4B market capitalization and 8.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CHYM Moat Profile Scale & Operating Efficiency Moat
Software - Application Operator
Competes within the Software - Application value chain with $12.7B market capitalization and 19.3% operating margin.
OpEx & R&D Reinvestment 70.1% of Rev ($10.1B)
90D Engineering Disclosures 0 Published

Investor FAQ PWP vs CHYM Key Questions & Quantitative Answers

As of Nov 16, 2026, Perella Weinberg Partners (PWP) captures the overall head-to-head institutional edge over Chime Financial, Inc. (CHYM) on higher Unified Composite conviction (47.4/100 HOLD vs. 33.1/100 SELL) after splitting the core matrix 5–5 (led by Growth & Scale, Profitability & Quality), while CHYM wins 4–2 across the 6-pillar growth and valuation breakdown. PWP trades at $12.89 (8.8x Forward P/E, 8.6% operating margin) versus CHYM at $34.25 (30.9x Forward P/E, 19.3% operating margin). Growth vs. Quality Trade-Off: PWP earns the overall head-to-head edge with a stronger Unified Composite Score (47.4/100 HOLD vs. CHYM 33.1/100 SELL) and 1.50β · 55% Vol risk profile, whereas CHYM leads top-line expansion (+32.1% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: PWP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 40.4); meanwhile CHYM trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 73.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

PWP leads the Growth & Scale pillar: PWP posts +52.7% YoY revenue growth and +153.4% YoY earnings growth on $776M TTM revenue (97.1% gross margin, 8.6% operating margin), compared with CHYM at +32.1% YoY revenue growth and -33.8% YoY earnings growth on $14.3B TTM revenue (89.4% gross margin, 19.3% operating margin). On trailing 12-month operating scale, PWP generates $776M in USD-normalized revenue versus $14.3B for CHYM. In operating R&D and SG&A reinvestment, PWP deploys N/A (0 90-day corporate R&D disclosures) versus 70.1% of Rev ($10.1B) (0 disclosures) for CHYM.

CHYM screens cheaper on headline valuation multiples. PWP trades at 8.8x Forward P/E, 34.5x Trailing P/E, N/M PEG, and 1.8x EV/Revenue (unreported cash flow margin), whereas CHYM trades at 30.9x Forward P/E, 29.0x Trailing P/E, N/M PEG, and 0.7x EV/Revenue (15.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PWP (15.2% ROE) versus CHYM (5.4% ROE) capital efficiency.

In options market volatility and institutional positioning, PWP carries 66.2% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.50β · 55% Vol realized risk). By comparison, CHYM carries 50.0% implied volatility (15th %ile, Compressed (<25th %ile)), a 0.22x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.44β · 37% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.